Research programme: zika virus vaccine - GlaxoSmithKline/NIH
Latest Information Update: 28 Aug 2020
At a glance
- Originator GlaxoSmithKline; National Institutes of Health (USA)
- Developer GSK; National Institutes of Health (USA)
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA
- 07 Jul 2016 Early research in Zika virus infection (Prevention) in USA (unspecified route)
Development Overview
Introduction
GlaxoSmithKline and National Institutes of Health (NIH) are collaborating to develop a vaccine to prevent spread of Zika virus infections. The company intends to utilise its novel self-amplifying mRNA (SAM) technology for the vaccine. Early research is currently underway in the US.
As at August 2020, no recent reports of development had been identified for research development in Zika-virus-infection (Prevention) in USA.
Key Development Milestones
In July 2016, GSK announced that the feasibility assessment studies for designing zika virus vaccine had completed and that the company is planning to initiate laboratory-based studies, in collaboration with various facilities at the NIH [1] .
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class RNA vaccines, Viral vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B (Viral Vaccines)
-
EPhMRA code
J7E (Viral Vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Zika virus infection | - | Prevention | No development reported (Research) | USA | unspecified / unspecified | GSK, National Institutes of Health (USA) | 28 Aug 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| GlaxoSmithKline | Originator | United-Kingdom |
| National Institutes of Health (USA) | Originator | USA |
| National Institutes of Health (USA) | Owner | USA |
| GlaxoSmithKline | Owner | United-Kingdom |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Aug 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Zika-virus-infection(Prevention) in USA Updated 28 Aug 2020 |
| 07 Jul 2016 | Phase Change | Early research in Zika virus infection (Prevention) in USA (unspecified route) Updated 27 Jul 2016 |
References
-
Update on GSK's response to the Zika virus disease outbreak.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG